logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn treats two coronavirus patients in Phase 2 trial

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan and diagnostic advisor to the group Dr Bruce Patterson tell Proactive the company has enrolled and begun treating the first two patients in its Phase 2 trial of leronlimab for people with mild-to-moderate coronavirus symptoms.

Pourhassan says the company expects enrollment to accelerate this week at multiple clinical sites, while separately, 15 severely ill coronavius patients have been treated with leronlimab so far, primarily in New York.

Quick facts: CytoDyn Inc.

Price: 4.845 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2.52 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

[email protected] Capital CEO discusses new Head of Enterprise Risk Management hire

[email protected] Capital PLC's (LON:SYME) Alessandro Zamboni speaks to Proactive following the announcement they've appointed Stuart Nelson as Head of Enterprise Risk Management (ERM). Zamboni says Nelson is a highly experienced credit analyst with experience assessing risk across multiple product...

2 hours, 28 minutes ago

2 min read